Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 5/20 | 0.50 |
| ▸ | ADH1C | P00326 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | EBP | Q15125 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611858 | 1.00 | ADH1A (0.50) | ADH1AADH1CALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL613463 | 1.00 | ADH1A (0.50) | ADH1AADH1CALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL612572 | 1.00 | ADH1A (0.50) | ADH1AADH1CALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL28388990 | 1.00 | ADH1A (0.50) | ADH1AADH1CALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL150343 | 1.00 | ADH1A (0.50) | ADH1AADH1CALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL23073672 | 1.00 | ADH1A (0.50) | ADH1AADH1CALDH1A1SMN1; SMN2MEN1 | |
| Fluoride SCHEMBL9620456 | 0.97 | ADH1A (0.48) | ADH1AADH1CALDH1A1SMN1; SMN2MEN1 | |
| Water SCHEMBL29014909 | 0.97 | ADH1A (0.48) | ADH1AADH1CALDH1A1SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL2142268 | 0.97 | ADH1A (0.48) | ADH1AADH1CALDH1A1SMN1; SMN2MEN1 | |
| Phosphine SCHEMBL27880090 | 0.97 | ADH1A (0.48) | ADH1AADH1CALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865217-B2 | Process for the preparation of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and polymorphs thereof | MSN LABORATORIES PRIVATE LIMITED, R & D CENTER (IN) | 2020-12-15 | — | — | US | claimed |
| US-20200190120-A1 | PROCESS FOR THE PREPARATION OF 5-(4-CYANOPHENOXY)-1,3-DIHYDRO-1-HYDROXY-[2,1]-BENZOXABOROLE AND POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2020-06-18 | — | — | US | claimed |
| WO-2018216032-A1 | PROCESS FOR THE PREPARATION OF 5-(4-CYANOPHENOXY)-1,3-DIHYDRO-1-HYDROXY-[2,1]-BENZOXABOROLE AND POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-11-29 | — | — | WO | claimed |
| US-8487105-B2 | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-07-16 | — | — | US | claimed |
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2012-01-19 | — | — | US | claimed |
| WO-2011148392-A1 | PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | WO | claimed |
| EP-2387561-A2 | IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE (3R,5S)-7-Ý2-CYCLOPROPYL-4-(4-FLUOROPHENYL) QUINOLIN-3-YL¨-3,5-DIHYDROXY-6(E)-HEPTENOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN Laboratories Limited (IN) | 2011-11-23 | — | — | EP | claimed |
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | claimed |
| WO-2010089770-A2 | IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE (3R,5S)-7-[2-CYCLOPROPYL-4-(4-FLUOROPHENYL) QUINOLIN-3-YL]-3,5-DIHYDROXY-6(E)-HEPTENOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN LABORATORIES LIMITED (IN) | 2010-08-12 | — | — | WO | claimed |
| EP-1307458-B1 | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES | ALMIRALL LAB (ES) | 2007-10-03 | — | — | EP | claimed |
| EP-1198464-B1 | 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2003-10-08 | — | — | EP | claimed |
| US-20030120086-A1 | New salts of HMG-CoA reductase inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2003-06-26 | — | — | US | claimed |
| US-6583295-B1 | Amine salts of such as lovastatin, pravastatin, simvastatin, mevastatin or atorvastatin | LEK PHARMACEUTICALS D.D. (SI) | 2003-06-24 | — | — | US | claimed |
| EP-1307458-A1 | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2003-05-07 | — | — | EP | claimed |
| US-20030060627-A1 | 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2003-03-27 | — | — | US | claimed |
| EP-1198464-A1 | 8-PHENYL-6,9-DIHYDRO- 1,2,4]TRIAZOLO 3,4- i i /i ]PURIN-5-ONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2002-04-24 | — | — | EP | claimed |
| WO-2002012246-A1 | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2002-02-14 | — | — | WO | claimed |
| EP-1114021-A1 | NEW SALTS OF HMG-CoA REDUCTASE INHIBITORS | Lek Pharmaceutical and Chemical Co. D.D. (SI) | 2001-07-11 | — | — | EP | claimed |
| WO-2001007441-A1 | 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2001-02-01 | — | — | WO | claimed |
| WO-2000017150-A1 | NEW SALTS OF HMG-CoA REDUCTASE INHIBITORS | LEK PHARMACEUTICAL AND CHEMICAL COMPANY D.D. (DE) | 2000-03-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | PCSK9, HMGCR, HDLBP | ADH1A 3579/4885ADH1C 3777/4885ALDH1A1 3826/4885 |
| US-20030060627-A1 | 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives | HYOU1, CHN2, PURB | ADH1A 1437/4885ADH1C 2083/4885ALDH1A1 1064/4885 |
| US-10865217-B2 | Process for the preparation of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole and polymorphs thereof | CYP1B1, CYP4B1, CYP1A1 | ADH1A 53/4885ADH1C 81/4885ALDH1A1 114/4885 |
| US-20200190120-A1 | PROCESS FOR THE PREPARATION OF 5-(4-CYANOPHENOXY)-1,3-DIHYDRO-1-HYDROXY-[2,1]-BENZOXABOROLE AND POLYMORPHS THEREOF | CYP1B1, CYP4B1, CYP1A1 | ADH1A 53/4885ADH1C 81/4885ALDH1A1 114/4885 |
| US-20030120086-A1 | New salts of HMG-CoA reductase inhibitors | HMGCR, COASY, FDPS | ADH1A 403/4885ADH1C 475/4885ALDH1A1 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.